Literature DB >> 28388255

Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal.

Floor J E Lubberman1, Nielka P van Erp1, Rob Ter Heine1, Carla M L van Herpen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28388255     DOI： 10.1080/0284186X.2017.1311024

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  8 in total

1.  Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinoma.

Authors:  G Beinse; A Hulin; Benoit Rousseau
Journal:  Invest New Drugs       Date:  2019-02-26       Impact factor: 3.850

2.  Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites.

Authors:  Stefanie D Krens; Sasja F Mulder; Nielka P van Erp
Journal:  Cancer Chemother Pharmacol       Date:  2021-12-01       Impact factor: 3.288

Review 3.  Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions.

Authors:  Eric D Eisenmann; Zahra Talebi; Alex Sparreboom; Sharyn D Baker
Journal:  Basic Clin Pharmacol Toxicol       Date:  2021-06-28       Impact factor: 4.080

4.  Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition.

Authors:  Eric D Eisenmann; Qiang Fu; Elizabeth M Muhowski; Yan Jin; Muhammad Erfan Uddin; Dominique A Garrison; Robert H Weber; Jennifer Woyach; John C Byrd; Alex Sparreboom; Sharyn D Baker
Journal:  Cancer Res Commun       Date:  2021-11-09

5.  Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib.

Authors:  René J Boosman; Cornedine J de Gooijer; Stefanie L Groenland; Jacobus A Burgers; Paul Baas; Vincent van der Noort; Jos H Beijnen; Alwin D R Huitema; Neeltje Steeghs
Journal:  Pharm Res       Date:  2022-03-29       Impact factor: 4.580

6.  Pharmacokinetically-guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients.

Authors:  Simon E Koele; Stijn W van Beek; Anthonie J van der Wekken; Berber Piet; Michel M van den Heuvel; Rob Ter Heine
Journal:  Br J Clin Pharmacol       Date:  2021-10-07       Impact factor: 3.716

7.  Cobicistat: A case of mislabelled drug-drug interaction risk?

Authors:  David M Burger; Alexandra Calmy; Catia Marzolini
Journal:  Br J Clin Pharmacol       Date:  2020-03-06       Impact factor: 4.335

8.  Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat.

Authors:  Nicolas Hohmann; Farastuk Bozorgmehr; Petros Christopoulos; Gerd Mikus; Antje Blank; Jürgen Burhenne; Michael Thomas; Walter E Haefeli
Journal:  Clin Transl Sci       Date:  2020-11-22       Impact factor: 4.689
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.